Skip to main content
Figure 1 | Genome Medicine

Figure 1

From: Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury

Figure 1

Serum alanine transaminase activity, CRP and haptoglobin prior to and after treatment of healthy subjects receiving 4 g of acetaminophen daily for 7 days. (A) Serum alanine transaminase activity (ALT) prior to and after APAP treatment of healthy subjects for 7 days. Depicted are ALT activities of DILI-responders versus non-responders receiving the same APAP dose. ALT activity in placebo-treated healthy volunteers is also shown. Note that the ALT activity was unchanged between pre-treatment and day 1 measurements. (B) CRP serum concentration of DILI responders with either high CRP (n = 3 healthy individuals) or all DILI responders, DILI non-responders and placebo-treated healthy subjects at baseline, day 1 and day 7 of APAP treatment. CRP measurements combined for day 1 and day 7 are also shown. (C) Haptoglobin serum concentration of DILI responders with either high haptoglobin (n = 3 healthy individuals) or all DILI responders, DILI non-responders and placebo-treated healthy subjects at baseline (day =0), day 1 and day 7 of APAP treatment. Haptoglobin measurements combined for day 1 and day 7 are also shown. ***P < 0.001; **P < 0.01; *P < 0.050; ns, not significant.

Back to article page